These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 22560921)

  • 81. An updated meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer.
    Shao N; Jin S; Zhu W
    J Thorac Oncol; 2012 Feb; 7(2):470-2. PubMed ID: 22252565
    [No Abstract]   [Full Text] [Related]  

  • 82. A multicenter, randomized, phase 3 trial comparing fixed dose versus toxicity-adjusted dose of cisplatin + etoposide in extensive small-cell lung cancer (SCLC) patients: The Small-cell-lung cancer Toxicity Adjusted Dosing (STAD-1) trial.
    Morabito A; Daniele G; Costanzo R; Favaretto AG; Filipazzi V; Rossi A; Gebbia V; Castiglione F; Cavanna L; Maiello E; Sandomenico C; Bonanno L; Piazza E; Maione P; Piccirillo MC; Di Maio M; Rocco G; Gallo C; Perrone F; Gridelli C
    Lung Cancer; 2017 Jun; 108():15-21. PubMed ID: 28625627
    [TBL] [Abstract][Full Text] [Related]  

  • 83. A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer.
    Han JY; Lim KY; Yu SY; Yun T; Kim HT; Lee JS
    Cancer; 2011 May; 117(10):2178-85. PubMed ID: 21523731
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).
    Zappa F; Droege C; Betticher D; von Moos R; Bubendorf L; Ochsenbein A; Gautschi O; Oppliger Leibundgut E; Froesch P; Stahel R; Hess T; Rauch D; Schmid P; Mayer M; Crowe S; Brauchli P; Ribi K; Pless M;
    Lung Cancer; 2012 Dec; 78(3):239-44. PubMed ID: 23009726
    [TBL] [Abstract][Full Text] [Related]  

  • 85. A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer.
    Schmittel A; Sebastian M; Fischer von Weikersthal L; Martus P; Gauler TC; Kaufmann C; Hortig P; Fischer JR; Link H; Binder D; Fischer B; Caca K; Eberhardt WE; Keilholz U;
    Ann Oncol; 2011 Aug; 22(8):1798-804. PubMed ID: 21266516
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC.
    Arriola E; Wheater M; Galea I; Cross N; Maishman T; Hamid D; Stanton L; Cave J; Geldart T; Mulatero C; Potter V; Danson S; Woll PJ; Griffiths R; Nolan L; Ottensmeier C
    J Thorac Oncol; 2016 Sep; 11(9):1511-21. PubMed ID: 27296105
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A feasibility study of carboplatin plus irinotecan treatment for elderly patients with extensive disease small-cell lung cancer.
    Misumi Y; Nishio M; Takahashi T; Ohyanagi F; Horiike A; Murakami H; Kenmotsu H; Yamamoto N; Ishii M; Shimokawa T; Hida N; Okamoto H
    Jpn J Clin Oncol; 2014 Feb; 44(2):116-21. PubMed ID: 24338555
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Irinotecan as a second-line monotherapy for small cell lung cancer.
    Sevinc A; Kalender ME; Altinbas M; Ozkan M; Dikilitas M; Camci C;
    Asian Pac J Cancer Prev; 2011; 12(4):1055-9. PubMed ID: 21790251
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
    Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Hypoxia-inducible factor-1α and excision repair cross-complementing 1 in patients with small cell lung cancer who received front-line platinum-based chemotherapy: a retrospective study.
    Lee GW; Go SI; Cho YJ; Jeong YY; Kim HC; Duk Lee J; Hwang YS; Ko GH; Lee JH; Kim DC; Yang JW; Oh S; Lee JS
    J Thorac Oncol; 2012 Mar; 7(3):528-34. PubMed ID: 22258474
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer.
    Kinoshita A; Fukuda M; Soda H; Nagashima S; Fukuda M; Takatani H; Kuba M; Nakamura Y; Tsurutani J; Kohno S; Oka M;
    Br J Cancer; 2006 May; 94(9):1267-71. PubMed ID: 16622467
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.
    Socinski MA; Novello S; Brahmer JR; Rosell R; Sanchez JM; Belani CP; Govindan R; Atkins JN; Gillenwater HH; Pallares C; Tye L; Selaru P; Chao RC; Scagliotti GV
    J Clin Oncol; 2008 Feb; 26(4):650-6. PubMed ID: 18235126
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients.
    Zarogoulidis K; Eleftheriadou E; Kontakiotis T; Gerasimou G; Zarogoulidis P; Sapardanis I; Galaktidou G; Sakkas L; Gotzamani-Psarrakou A; Karatzas N
    Lung Cancer; 2012 Apr; 76(1):84-8. PubMed ID: 22018594
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small Cell Lung Cancer.
    Reck M; Horn L; Novello S; Barlesi F; Albert I; Juhász E; Kowalski D; Robinet G; Cadranel J; Bidoli P; Chung J; Fritsch A; Drews U; Wagner A; Govindan R
    J Thorac Oncol; 2019 Apr; 14(4):701-711. PubMed ID: 30677506
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease.
    Socinski MA; Kaye FJ; Spigel DR; Kudrik FJ; Ponce S; Ellis PM; Majem M; Lorigan P; Gandhi L; Gutierrez ME; Nepert D; Corral J; Ares LP
    Clin Lung Cancer; 2017 Jan; 18(1):68-76.e2. PubMed ID: 28341109
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study.
    Byers LA; Bentsion D; Gans S; Penkov K; Son C; Sibille A; Owonikoko TK; Groen HJM; Gay CM; Fujimoto J; de Groot P; Dunbar M; Kang K; He L; Sehgal V; Glasgow J; Bach BA; Ellis PM
    Clin Cancer Res; 2021 Jul; 27(14):3884-3895. PubMed ID: 33947690
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.
    Pujol JL; Lavole A; Quoix E; Molinier O; Souquet PJ; Barlesi F; Le Caer H; Moro-Sibilot D; Fournel P; Oster JP; Chatellain P; Barre P; Jeannin G; Mourlanette P; Derollez M; Herman D; Renault A; Dayen C; Lamy PJ; Langlais A; Morin F; Zalcman G;
    Ann Oncol; 2015 May; 26(5):908-914. PubMed ID: 25688059
    [TBL] [Abstract][Full Text] [Related]  

  • 98. A phase II study of sunitinib in advanced hepatocellular carcinoma.
    Barone C; Basso M; Biolato M; Pompili M; Rufini V; Miele L; Basso M; De Gaetano AM; Castaldi P; Iaculli A; Leccisotti L; Riccardi L; Grieco A
    Dig Liver Dis; 2013 Aug; 45(8):692-8. PubMed ID: 23410734
    [TBL] [Abstract][Full Text] [Related]  

  • 99. A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancer.
    Grilley-Olson JE; Keedy VL; Sandler A; Moore DT; Socinski MA; Stinchcombe TE
    Oncologist; 2015 Feb; 20(2):105-6. PubMed ID: 25616430
    [TBL] [Abstract][Full Text] [Related]  

  • 100. A Phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small-cell lung cancer (JCOG1201).
    Eba J; Shimokawa T; Nakamura K; Shibata T; Misumi Y; Okamoto H; Yamamoto N; Ohe Y;
    Jpn J Clin Oncol; 2015 Jan; 45(1):115-8. PubMed ID: 25332420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.